CN112004790A - 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 - Google Patents

一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN112004790A
CN112004790A CN201980023555.9A CN201980023555A CN112004790A CN 112004790 A CN112004790 A CN 112004790A CN 201980023555 A CN201980023555 A CN 201980023555A CN 112004790 A CN112004790 A CN 112004790A
Authority
CN
China
Prior art keywords
optionally substituted
compound
hydrogen
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023555.9A
Other languages
English (en)
Inventor
张龙
宋国伟
周凯松
李佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of CN112004790A publication Critical patent/CN112004790A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/02—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/02—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/16—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a six-membered ring
    • C07C13/18—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a six-membered ring with a cyclohexane ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems

Abstract

本发明属于药物化学领域，公开了一种新型吲哚胺2，3‑双加氧酶抑制剂及其制备方法和用途。本发明中的吲哚胺2，3‑双加氧酶(IDO)抑制剂的结构如式I所示，具有抗肿瘤、抗神经退行性疾病、抗炎等多种药理活性。
Figure DDA0002708604700000011

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980023555.9A 2018-04-09 2019-04-08 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 Pending CN112004790A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018103110779 2018-04-09
CN201810311077.9A CN110357813A (zh) 2018-04-09 2018-04-09 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
PCT/CN2019/081709 WO2019196780A1 (zh) 2018-04-09 2019-04-08 一种新型吲哚胺2，3-双加氧酶抑制剂及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN112004790A true CN112004790A (zh) 2020-11-27

Family

ID=68163866

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810311077.9A Pending CN110357813A (zh) 2018-04-09 2018-04-09 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
CN201980023555.9A Pending CN112004790A (zh) 2018-04-09 2019-04-08 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810311077.9A Pending CN110357813A (zh) 2018-04-09 2018-04-09 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途

Country Status (2)

Country Link
CN (2) CN110357813A (zh)
WO (1) WO2019196780A1 (zh)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063839A1 (ja) * 2005-11-30 2007-06-07 Shionogi & Co., Ltd. シクロヘキサン誘導体
CN106535884A (zh) * 2014-06-06 2017-03-22 弗雷克萨斯生物科学公司 免疫调节剂
CN106999450A (zh) * 2014-11-05 2017-08-01 弗莱塞斯生物科学公司 免疫调节剂
CN107021929A (zh) * 2016-01-29 2017-08-08 苏州国匡医药科技有限公司 一类新型ido抑制剂、制备方法、药物组合物及其用途
CN107205970A (zh) * 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
CN107427499A (zh) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 免疫调节剂
WO2018017529A1 (en) * 2016-07-19 2018-01-25 Bristol-Myers Squibb Company Radioligands for imaging the ido1 enzyme
CN109843872A (zh) * 2017-09-20 2019-06-04 杭州英创医药科技有限公司 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CN109928916A (zh) * 2017-12-18 2019-06-25 成都华健未来科技有限公司 一类作为ido抑制剂的喹啉-4-基环己烷类化合物
CN110092750A (zh) * 2018-01-29 2019-08-06 北京诺诚健华医药科技有限公司 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用
CN111093651A (zh) * 2017-06-30 2020-05-01 百时美施贵宝公司 Ido抑制剂的无定形和结晶形式
CN111655264A (zh) * 2017-06-30 2020-09-11 百时美施贵宝公司 经取代的喹啉基环己基丙酰胺化合物和改进的其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048109A1 (en) * 2001-12-03 2003-06-12 Novo Nordisk A/S Novel glucagon antagonists
EP1864971A4 (en) * 2005-03-31 2010-02-10 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063839A1 (ja) * 2005-11-30 2007-06-07 Shionogi & Co., Ltd. シクロヘキサン誘導体
CN106535884A (zh) * 2014-06-06 2017-03-22 弗雷克萨斯生物科学公司 免疫调节剂
CN106999450A (zh) * 2014-11-05 2017-08-01 弗莱塞斯生物科学公司 免疫调节剂
CN107205970A (zh) * 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
CN107427499A (zh) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 免疫调节剂
CN107021929A (zh) * 2016-01-29 2017-08-08 苏州国匡医药科技有限公司 一类新型ido抑制剂、制备方法、药物组合物及其用途
WO2018017529A1 (en) * 2016-07-19 2018-01-25 Bristol-Myers Squibb Company Radioligands for imaging the ido1 enzyme
CN111093651A (zh) * 2017-06-30 2020-05-01 百时美施贵宝公司 Ido抑制剂的无定形和结晶形式
CN111655264A (zh) * 2017-06-30 2020-09-11 百时美施贵宝公司 经取代的喹啉基环己基丙酰胺化合物和改进的其制备方法
CN109843872A (zh) * 2017-09-20 2019-06-04 杭州英创医药科技有限公司 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CN109928916A (zh) * 2017-12-18 2019-06-25 成都华健未来科技有限公司 一类作为ido抑制剂的喹啉-4-基环己烷类化合物
CN110092750A (zh) * 2018-01-29 2019-08-06 北京诺诚健华医药科技有限公司 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MUNIA F SOWAILEH 等: "Application of the Pentafluorosulfanyl Group as a Bioisosteric Replacement", 《CHEMMEDCHEM》 *
NELP, MT等: "Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》 *
QIU, ZH等: "Formal aromaticity transfer for palladiumcatalyzed coupling between phenols and pyrrolidines/indolines", 《CHEMICAL SCIENCE》 *
STN: "《STN》", 2 June 2016 *

Also Published As

Publication number Publication date
CN110357813A (zh) 2019-10-22
WO2019196780A1 (zh) 2019-10-17

Similar Documents

Publication Publication Date Title
CN113651814B (zh) Kras突变蛋白抑制剂
KR102482673B1 (ko) 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도
CN111484477B (zh) 一种苯并吡啶酮杂环化合物及其用途
WO2021023154A1 (zh) 四并环类化合物及其制备方法和应用
KR20210089195A (ko) 비페닐계 화합물, 이의 중간체, 제조 방법, 약학 조성물 및 용도
CN110092745B (zh) 一种含芳环的化合物及其应用
WO2020011246A1 (zh) 含苯环的化合物、其制备方法及应用
KR20140131955A (ko) 신규 트리아진 유도체
KR20100016432A (ko) Ｐｉ３ｋ 저해제로서 2-모르폴린-4-일-피리미딘
JP2020512399A (ja) Ｉｄｏを抑制する化合物、その調製方法及びその使用
CN112851663B (zh) 一种并杂环化合物及其用途
CN110041253B (zh) 吡啶类n-氧化衍生物及其制备方法和应用
CN115353508B (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN113024544A (zh) 一种含氰基并杂环化合物及其用途
CN112745335A (zh) 一种三并杂环化合物及其用途
WO2020192650A1 (zh) 酰胺类化合物制备方法及其在医药领域的应用
WO2021047553A1 (zh) 含三环结构的芳香杂环化合物，及其制备方法和应用
JP2022550489A (ja) スルホ置換ビアリール化合物又はその塩並びにその調製方法及び使用
CN112004790A (zh) 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
JP2017525734A (ja) 癌の治療において有用なイソキノリノン誘導体
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN112839931B (zh) 1,2,3,4-四氢喹喔啉衍生物及其制备方法和应用
CN111848572B (zh) 酰胺类化合物及其制备方法和用途
CN109836385B (zh) 四氢喹啉类n-氧化衍生物及其制备方法和应用
WO2021197467A1 (zh) 多靶点的抗肿瘤化合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201127